{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:26:35Z","timestamp":1792207595415,"version":"4.4.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg\/d in 63 patients with relapsed\/refractory MZL treated with prior rituximab (RTX) or rituximab-based chemoimmunotherapy (RTX-CIT). We report the final analysis of PCYC-1121 with median follow-up of 33.1 months (range: 1.4-44.6). Overall response rate (ORR) was 58%; median duration of response (DOR) was 27.6 months (95% confidence interval [CI]: 12.1 to not estimable [NE]); median progression-free survival (PFS) was 15.7 months (95% CI: 12.2-30.4); and median overall survival (OS) was not reached (95% CI: NE to NE). Patients with prior RTX treatment had better outcomes (ORR: 81%; median DOR: not reached [95% CI: 12.2 to NE]; median PFS: 30.4 months [95% CI: 22.1 to NE]; median OS: not reached [95% CI: 30.3 to NE]) vs those with prior RTX-CIT treatment (ORR: 51%; DOR: 12.4 months [95% CI: 2.8 to NE]; PFS: 13.8 months [95% CI: 8.3-22.5]; OS: not reached [95% CI: NE to NE]). ORRs were 63%, 47%, and 62% for extranodal, nodal, and splenic subtypes, respectively. With up to 45 months of ibrutinib treatment, the safety profile remained consistent with prior reports. The most common grade \u22653 event was anemia (16%). Exploratory biomarker analysis showed NF-\u03baB pathway gene mutations correlated with outcomes. Final analysis of PCYC-1121 demonstrated long-term safety and efficacy of ibrutinib in patients with relapsed\/refractory MZL, regardless of prior treatment or MZL subtype. This trial was registered at www.clinicaltrials.gov as #NCT01980628.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003121","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T21:08:23Z","timestamp":1607029703000},"page":"5773-5784","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4898","authenticated-orcid":false,"given":"Ariela","family":"Noy","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"de Vos","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8516-2513","authenticated-orcid":false,"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham P.","family":"Collins","sequence":"additional","affiliation":[{"name":"Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shachar","family":"Peles","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists, Atlantis, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7593","authenticated-orcid":false,"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Washington\/Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, New Hyde Park, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Chong","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiquan","family":"Wu","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo W.-K.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kwei","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hauns","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Arango-Hisijara","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"issue":"6","key":"2020120315430578600_B1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2020120315430578600_B2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"key":"2020120315430578600_B3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/CMAR.S133291","article-title":"Management of relapsed\/refractory marginal zone lymphoma: focus on ibrutinib","volume":"10","author":"Denlinger","year":"2018","journal-title":"Cancer Manag Res"},{"key":"2020120315430578600_B4","author":"Zucca"},{"issue":"17","key":"2020120315430578600_B5","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2020120315430578600_B6","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2020120315430578600_B7","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020120315430578600_B8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00277-018-3501-8","article-title":"Burden of illness of follicular lymphoma and marginal zone lymphoma","volume":"98","author":"Monga","year":"2019","journal-title":"Ann Hematol"},{"issue":"6","key":"2020120315430578600_B9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia","volume":"40","author":"Bhatia","year":"2013","journal-title":"Semin Oncol"},{"issue":"6","key":"2020120315430578600_B10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"2020120315430578600_B11","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/ijc.29326","article-title":"Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma","volume":"136","author":"Bernard","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"2020120315430578600_B12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies [published correction appears in Mol Cancer. 2019;18(1):79]","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"1","key":"2020120315430578600_B13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton\u2019s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"issue":"5","key":"2020120315430578600_B14","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2020120315430578600_B15","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"key":"2020120315430578600_B16","volume-title":"Imbruvica (ibrutinib)","year":"2020"},{"issue":"16","key":"2020120315430578600_B17","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020120315430578600_B18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020120315430578600_B19","doi-asserted-by":"crossref","first-page":"17038","DOI":"10.18632\/oncotarget.14928","article-title":"The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"2020120315430578600_B20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/joim.12633","article-title":"Genetic landscape and deregulated pathways in B-cell lymphoid malignancies","volume":"282","author":"Rosenquist","year":"2017","journal-title":"J Intern Med"},{"issue":"10","key":"2020120315430578600_B21","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2020120315430578600_B22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/07357907.2016.1212062","article-title":"Salvage chemotherapy with R-DHAP in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"34","author":"Schirmbeck","year":"2016","journal-title":"Cancer Invest"},{"issue":"19","key":"2020120315430578600_B23","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020120315430578600_B24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"8","key":"2020120315430578600_B25","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2020120315430578600_B26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","article-title":"A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"145","author":"Brown","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2020120315430578600_B27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/annonc\/mdp395","article-title":"Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)","volume":"21","author":"Cervetti","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"2020120315430578600_B28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.leukres.2009.04.003","article-title":"2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma","volume":"34","author":"Orciuolo","year":"2010","journal-title":"Leuk Res"},{"issue":"5","key":"2020120315430578600_B29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020120315430578600_B30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hon.2334","article-title":"The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma","volume":"35","author":"Laribi","year":"2017","journal-title":"Hematol Oncol"},{"issue":"6","key":"2020120315430578600_B31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000098555","article-title":"Activity of rituximab plus cyclophosphamide, doxorubicin\/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma","volume":"70","author":"Raderer","year":"2006","journal-title":"Oncology"},{"issue":"2","key":"2020120315430578600_B32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-013-1865-3","article-title":"Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"93","author":"Kiesewetter","year":"2014","journal-title":"Ann Hematol"},{"issue":"35","key":"2020120315430578600_B33","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma [published correction appears in J Clin Oncol. 2018;36(5):521]","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020120315430578600_B34","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"2020120315430578600_B35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020120315430578600_B36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020120315430578600_B37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2020120315430578600_B38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-16-1431","article-title":"Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"23","author":"Coutr\u00e9","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2020120315430578600_B39","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"2020120315430578600_B40","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2020120315430578600_B41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.15421","article-title":"Evaluation of 230 patients with relapsed\/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials","volume":"182","author":"Jones","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"2020120315430578600_B42","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2020120315430578600_B43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"issue":"17","key":"2020120315430578600_B44","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020120315430578600_B45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-018-0626-0","article-title":"Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study","volume":"11","author":"Reda","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2020120315430578600_B46","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"key":"2020120315430578600_B47","doi-asserted-by":"crossref","first-page":"406","DOI":"10.12688\/f1000research.13826.1","article-title":"Recent advances in understanding the biology of marginal zone lymphoma","volume":"7","author":"Bertoni","year":"2018","journal-title":"F1000 Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/22\/5773\/1790691\/advancesadv2020003121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/22\/5773\/1790691\/advancesadv2020003121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T21:08:55Z","timestamp":1607029735000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/22\/5773\/474232\/Durable-ibrutinib-responses-in-relapsedrefractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":47,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003121","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]}}}